-
Loading metrics
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation
-
Michael J. Thomenius ,
Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing
* E-mail: mthomenius@epizyme.com
Affiliation Epizyme, Inc., Cambridge, Massachusetts, United States of America
⨯ - Jennifer Totman,
- Darren Harvey,
- Lorna H. Mitchell,
- Thomas V. Riera,
- Kat Cosmopoulos,
- Alexandra R. Grassian,
- Christine Klaus,
- Megan Foley,
- Elizabeth A. Admirand,
- Haris Jahic,
- Christina Majer,
- Tim Wigle,
- Suzanne L. Jacques,
- Jodi Gureasko,
- Dorothy Brach,
- Trupti Lingaraj,
- Kip West,
- Sherri Smith,
- Nathalie Rioux,
- Nigel J. Waters,
- Cuyue Tang,
- Alejandra Raimondi,
- Michael Munchhof,
- James E. Mills,
- Scott Ribich,
- Margaret Porter Scott,
- Kevin W. Kuntz,
- William P. Janzen,
- Mikel Moyer,
- Jesse J. Smith,
- Richard Chesworth,
- Robert A. Copeland,
- [ ... ],
- P. Ann Boriack-Sjodin
- [ view all ]
- [ view less ]
http://orcid.org/0000-0002-3357-7872
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation
- Michael J. Thomenius,
- Jennifer Totman,
- Darren Harvey,
- Lorna H. Mitchell,
- Thomas V. Riera,
- Kat Cosmopoulos,
- Alexandra R. Grassian,
- Christine Klaus,
- Megan Foley,
- Elizabeth A. Admirand
x
- Published: June 1, 2018
- https://doi.org/10.1371/journal.pone.0197372